NanoViricides Inc. (NNVC): Market Cap to Revenue Ratio

Corporate company logo of nanoviricides.com (NNVC)

The price-to-sales ratio dynamics demonstrate how the market values the nanotechnological foundation of NanoViricides, Inc. (NNVC), which provides intellectual property protection prior to the growth of cash flows. However, intense competition in the mRNA solutions sector creates risks for the project. Currently, the R&D center is developing unique drugs against viral infections, and the parameter has stabilized at , determining the current business valuation.

Price-to-Revenue Ratio: NanoViricides Corp (NNVC) for 07/04/2022 - 11/13/2026

NanoViricides, Inc. (NNVC) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Chart nanoviricides.com|NNVC - Price Target Chart
- stock exchange capitalization data:
Market Capitalization NanoViricides Corp|NNVC - Enterprise Value
- business book valuation details:
Book Value per Share NanoViricides|NNVC - Company Book Value|Capitalization to Book Value Ratio nanoviricides.com|NNVC - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Capital NanoViricides, Inc.|NNVC - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity nanoviricides.com|NNVC - Company Aggregate Debts|Debts to Net Assets NanoViricides Corp|NNVC - Company Long-Term Debt|Company Short-Term Loans and Borrowings NanoViricides|Interim Coverage Ratio nanoviricides.com
- company profitability and valuation multiples indicators:
NNVC - Net Profit|Future Profit NanoViricides, Inc.|NNVC - P/E Multiple|Market Cap to Projected Earnings nanoviricides.com|NNVC - PEG Multiple|Enterprise Value to Operating Income Before Depreciation NanoViricides Corp|NNVC - Operating profit EBITDA|Net earnings per one share for the last twelve months NanoViricides|NNVC - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months nanoviricides.com|NNVC - Net earnings per share growth this year|Expected earnings per share trend next year NanoViricides, Inc.
- total revenue and sales volume data:
NNVC - Revenue and Sales Volume|Company Future Sales nanoviricides.com|NNVC - Price-to-Revenue Ratio|Market Cap to Projected Revenue NanoViricides Corp
General company analysis:NNVC, NanoViricides Inc.
Mass-produced product of nanoviricides.com

The development of antiviral nanopreparations by NanoViricides, Inc. (NNVC) is independent of macroeconomic cycles, relying exclusively on clinical trial results. The P/S multiple compares the business's market capitalization with its annual sales volume, determining the cost of each unit of revenue. This metric allows for an assessment of the premium paid for the company's future technological successes. By analyzing the revenue multiple dynamics, an investor can timely identify entry points and minimize the risks of asset overvaluation.

Competitors of NanoViricides, Inc.

Price-to-Revenue Coefficient gilead.com|Price-to-Revenue Ratio Cidara Therapeutics Inc CDTX|NVAX: Market Cap to Revenue Ratio|CureVac Corp - P/S Multiple|VALN - P/S Multiple|Vir Biotechnology, Inc. (VIR) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio SIGA|Price-to-Revenue Ratio Emergent BioSolutions Inc.|Price to Sales Atea Pharma AVIR|Market Cap to Revenue IVVD (Invivyd, Inc.)|Price-to-Revenue Ratio ENTA (Enanta Pharmaceuticals, Inc)|P/S Multiple INO (Inovio Pharmaceuticals)|Price-to-Revenue Coefficient hillevax.com (HLVX)|KLRS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio DYAI (Dyadic International)|TLPH: P/S Multiple|COCP - Price-to-Revenue Coefficient|TRAW (Traws Pharma Inc) - P/S Multiple|Market Cap to Revenue Virios Therapeutics (DWTX)|P/S Multiple QLGN|Price-to-Revenue Coefficient allovir.com|P/S Multiple VBIV (VBI Vaccines)|VIRI: Market Cap to Revenue Ratio|Vaxart Corp - P/S Multiple